Uncategorized

Opinion: FDA commissioner: ‘Smarter,’ real-time clinical trials could transform drug development

Why does it take a new drug 10 years, on average, to come to market? Part of the reason lies in the dead time in the process.  

Historically, trials have required tedious tabulations and repeated application submissions between phases, which is why 45% of the time from a Phase 1 trial until final submission is spent without any ongoing clinical trial in progress — idle time in the system.   

Read the rest…

Read More

Published

on

Why does it take a new drug 10 years, on average, to come to market? Part of the reason lies in the dead time in the process.  

Historically, trials have required tedious tabulations and repeated application submissions between phases, which is why 45% of the time from a Phase 1 trial until final submission is spent without any ongoing clinical trial in progress — idle time in the system.   

Read the rest…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version